## Abstract Existing and emerging strategies for managing Lβdopaβinduced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of Lβdopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dop
β¦ LIBER β¦
Therapy found for Parkinson's disease dyskinesia
β Scribed by Jane Bradbury
- Book ID
- 117283704
- Publisher
- The Lancet
- Year
- 2003
- Tongue
- English
- Weight
- 44 KB
- Volume
- 361
- Category
- Article
- ISSN
- 0140-6736
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Therapies for dopaminergic-induced dyski
β
Mildred D. Gottwald; Michael J. Aminoff
π
Article
π
2011
π
John Wiley and Sons
π
English
β 230 KB
π 2 views
Therapies for dopaminergic-induced dyski
β
John R. Ponsford
π
Article
π
2011
π
John Wiley and Sons
π
English
β 44 KB
π 2 views
Classifying risk factors for dyskinesia
β
J.C. Sharma; C.G. Bachmann; G. Linazasoro
π
Article
π
2010
π
Elsevier Science
π
English
β 228 KB
Lamotrigine induced dyskinesia in Parkin
β
M. Sabolek; U. Runge
π
Article
π
2010
π
John Wiley and Sons
π
English
β 66 KB
Levodopa-induced dyskinesia in Parkinson
β
J. M. Brotchie; J. Lee; K. Venderova
π
Article
π
2004
π
Springer
π
English
β 190 KB
Pain and dyskinesia in Parkinson's disea
β
Carlos Juri; Maria C. RodrΓguez-Oroz; Juan A. Burguera; Jorge Guridi; Jose A. Ob
π
Article
π
2009
π
John Wiley and Sons
π
English
β 178 KB
Lerner and Bagic 1 have to be congratulated for their hypothesis on PD pathogenesis. They suggest that the sequence of the brain changes in PD follows specific and repeatable patterns in all cases, as well as that a prion-like process underlies neurodegeneration. These ideas could explain several fe